How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,006 results for

Subcutaneous Fat Necrosis

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

102. Renal Cell Carcinoma

. 185: 2035. 89. Novara, G., et al. Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for renal cell carcinoma: are further improvements needed? Eur Urol, 2010. 58: 588. 90. Waalkes, S., et al. Is there a need to further subclassify pT2 renal cell cancers as implemented by the revised 7th TNM version? Eur Urol, 2011. 59: 258. 91. Bertini, R., et al. Renal sinus fat invasion in pT3a clear cell renal cell carcinoma affects outcomes of patients without nodal (...) involvement or distant metastases. J Urol, 2009. 181: 2027. 92. Poon, S.A., et al. Invasion of renal sinus fat is not an independent predictor of survival in pT3a renal cell carcinoma. BJU Int, 2009. 103: 1622. 93. Bedke, J., et al. Perinephric and renal sinus fat infiltration in pT3a renal cell carcinoma: possible prognostic differences. BJU Int, 2009. 103: 1349. 94. Heidenreich, A., et al. Preoperative imaging in renal cell cancer. World J Urol, 2004. 22: 307. 95. Sheth, S., et al. Current concepts

2019 European Association of Urology

104. Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease

to thiopurines. Despite the fact that certolizumab is FDA approved and used in the United States, it is not licensed for the treatment of CD in Canada or Europe and therefore was not included in this CPG. AZA, azathioprine; IM, intramuscular; MTX, methotrexate; SC, subcutaneous; TNF, tumor necrosis factor. e8 Journal of the Canadian Association of Gastroenterology, 2019, Vol. 2, No. 3T able 3. Summary of Consensus Recommendations for the Management of Luminal Crohn’s Disease a Disease activity 1. We (...) budesonide) can be used as induction, but not mainten- ance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies

2019 Canadian Association of Gastroenterology

105. A cost-utility analysis of biosimilar infliximab compared to reference infliximab in adult switch patients with Crohn’s disease: A Canadian analysis

in children, and high intake of total fat, polyunsaturated fatty acids, omega 6 fatty acids and red meat (Crohn's and Colitis Foundation of Canada, 2012). All of these factors may in part explain the high incidence and prevalence of CD in the Canadian environment. 1.4.3 Symptoms & Complications CD can lead to a number of symptoms and complications which affect both the intestinal tract and other parts of the body since it is a systemic disease (Gastrointestinal Society - Canadian Society of Intestinal (...) , & Lichtenstein, 2014). It starts with therapies that are less costly and/or with more preferable routes of administration, but potentially less effective. It escalates to the therapies which are more effective, but also more costly and with intravenous or subcutaneous administration (Lin et al., 2014). If a patient fails one level of therapy or becomes intolerant they are moved up to the next strategy (Lin et al., 2014). However, using this method also means that effective therapy may be delayed, with a risk

2019 SickKids Reports

107. BSG consensus guidelines on the management of inflammatory bowel disease in adults

; PDAI: Pouchitis Disease Activity Score; PEG: polyethylene glycol; PEO, Population, Exposure, Outcome; PICO: Population, Intervention, Comparator, Outcome; PRO: Patient Reported Outcome; PROM: Patient Reported Outcome Measure; RCT: randomised controlled trial; RR: relative risk; SBUS: small bowel ultrasound; SES-CD: Simplified Endoscopic activity Score for Crohn's disease; s.c.: subcutaneous; TB: tuberculosis; TGN: thioguanine nucleotides; THC: delta 9 -tetrahydrocannabionol; TNF: tumour necrosis

2019 British Society of Gastroenterology

108. Canadian Association of Gastroenterology Clinical Practice Guideline for the Medical Management of Pediatric Luminal Crohn’s Disease

and biologic tumor necrosis factor antagonists for induction and maintenance therapy at diagnosis or at early stages of se- vere disease, and for patients failed by steroid and immunosuppressant induction therapies. The group recommended against the use of oral 5-aminosalicylate for induction or maintenance therapy in pa- tients with moderate disease, and recommended against thiopurines for induction therapy, cortico- steroids for maintenance therapy, and cannabis in any role. The group was unable (...) an important therapeutic goal. 5 This may be especially important in young patients, given the potential for growth impairment as a direct effect of persistent chronic in- flammation 6,7 and their long lives ahead, during which disease complications may occur. Mucosal healing became a realistic goal for patients with the advent of monoclonal antibodies directed against tumor necrosis factor (TNF)-a. As alternate pathway biologic agents and new small molecule therapies emerge, it behooves clinicians

2019 Canadian Association of Gastroenterology

109. Adalimumab (Hyrimoz) - Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Crohn Disease, Papulosquamous Skin Diseases, Hidradenitis Suppurativa, Ankylosing Spondylitis, Uveitis

subcutaneous injection. Methotrexate should be continued during treatment with Hyrimoz. Glucocorticoids, salicylates, nonsteroidal anti-inflammatory drugs, or analgesics can be continued during treatment with Hyrimoz. Regarding combination with disease modifying anti-rheumatic drugs other than methotrexate see sections 4.4 and 5.1. 5 In monotherapy, some patients who experience a decrease in their response to Hyrimoz 40 mg every other week may benefit from an increase in dosage to 40 mg adalimumab every (...) with psoriatic arthritis is 40 mg adalimumab administered every other week as a single dose via subcutaneous injection. Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be reconsidered in a patient not responding within this time period. Psoriasis The recommended dose of Hyrimoz for adult patients is an initial dose of 80 mg administered subcutaneously, followed by 40 mg subcutaneously given every other week starting one week after

2018 European Medicines Agency - EPARs

110. Neratinib (Nerlynx) - Breast cancer, breast neoplasms

. Hepatic necrosis in 1/3 females. 700 mg/kg: no evidence of macroscopic changes. Assessment report EMA/CHMP/525204/2018 Page 25/169 RPT-48225 GLP Rat 3M:3F/Group 0, 200, 700, 2000 - IP 700/200 Mortality at 2000 & 700 mg/kg, with changes to adrenal gland, GI tract, and kidney. Renal tubular ectasia at 2000 mg/kg. 200 mg/kg: enlarged liver, fibrosis of stomach, small/large intestine, spleen, pancreas. In mice, no adverse effects were seen in doses of neratinib up to 2000 mg/kg. Single intraperitoneal (...) ), and signs of hepatic inflammation and necrosis. There were moderate increases in fibrinogen, white blood cells (WBC), neutrophils, lymphocytes, and monocytes, and decreases in cholesterol, total protein and albumin. Other findings High doses in the earlier dose-range finding studies in rats showed evidence of reproductive organ toxicity, prostatic and uterine atrophy leading to reduced prostate and uterus weights. In addition male rats experienced mammary gland atrophy (neratinib doses of =15 mg/kg/day

2018 European Medicines Agency - EPARs

111. Rucaparib camsylate - Ovarian Neoplasms

/kg BID rucaparib resulted in statistically significant inhibition of 45%, 86%, and 96% respectively. There was an inverse and dose-dependent correlation between PAR and rucaparib levels in the plasma and tumour. Although the tumour to plasma (T/P) ratio was lower at higher doses of rucaparib, the levels of rucaparib in the tumour were consistently higher than the levels of rucaparib in plasma. A further PK/PD study was performed in the subcutaneous MDA-MB-436 xenograft model. Animals were treated (...) lymph nodes, and thymic atrophy (correlated with decreased thymic weights at 75 mg/kg/day). Minimal to moderate myocardial degeneration, necrosis, and fibroplasia usually located at the apex of the heart were observed in males at 75 mg/kg/day. No associated changes in troponin T levels were noted on Day 6. The NOAEL for rucaparib in this study was considered to be 5 mg/kg/day, which corresponded to a mean combined male and female C max and AUC 0-24.5 of 672 ng/mL and 992 ng·hr/mL, respectively

2018 European Medicines Agency - EPARs

112. Cutaneous melanoma

with a 2 mm surround of normal skin and a cuff of fat. 63 This enables assessment of the entire lesion (see section 5.1). Elliptical excisions should be performed along the long axis in the line of a natural skin crease or longitudinally in limbs. The exact surgical margins of excision should be recorded on the operation note. Non-excisional biopsy may lead to inadequate histology. 64-68 The least useful type of biopsy is the superficial shave variety. Two large studies demonstrate that non-excisional (...) melanoma should be excised with a 2 mm margin and a cuff of fat. If complete excision cannot be performed as a primary procedure an incisional or punch biopsy of the most suspicious area is advised. A superficial shave biopsy is inappropriate for suspicious pigmented lesions. 4 GPs should refer urgently all patients in whom melanoma is a strong possibility rather than carry out a biopsy in primary care. Newly-diagnosed patients should receive both verbal and written information about melanoma including

2017 SIGN

113. Management of Acute Myocardial Infarction in patients presenting with ST-segment elevation

With Acute Myocardial Infarction RIFLE- STEACS Radial Versus Femoral Randomized Investigation in ST-Elevation Acute Coronary Syndrome RIVAL Radial Versus Femoral Access for Coronary intervention RV right ventricle/ventricular SaO 2 arterial oxygen saturation SBP systolic blood pressure s.c. subcutaneous SGLT2 sodium-glucose co-transporter-2 SPECT single-photon emission computed tomography STEMI ST-segment elevation myocardial infarction STREAM STrategic Reperfusion Early After Myocardial infarction TIMI (...) of evidence being based on expert opinion, this Task Force decided to add references to guide the reader regarding data that were taken into consideration for these decisions in some cases. 2.1 Definition of acute myocardial infarction The term acute myocardial infarction (AMI) should be used when there is evidence of myocardial injury (defined as an elevation of cardiac troponin values with at least one value above the 99th percentile upper reference limit) with necrosis in a clinical setting consistent

Full Text available with Trip Pro

2017 European Society of Cardiology

115. Atherosclerotic Cardiovascular Disease in South Asians in the United States: Epidemiology, Risk Factors, and Treatments: A Scientific Statement From the American Heart Association

had more visceral and deep subcutaneous fat compared with superficial subcutaneous fat. South Asians had a greater amount of abdominal adipose tissue compared with NHWs. A cross-sectional survey comparing Indians, Pakistani, Bangladeshi, and Europeans from the Newcastle Heart Project demonstrated higher rates of obesity based on BMI >30 kg/m 2 in Indian and Pakistani people compared with Bangladeshis. However, the WHR was higher in Bangladeshi and Pakistani people compared with Indians. When all (...) studies using BMI versus waist-to-hip ratio (WHR). One limitation of relying on BMI is that it does not take into account the distribution of body fat differentials, which may be better assessed with WHR. The MASALA study done in the United States showed that compared with NHWs, South Asians were less physically active and had lower adiponectin and higher resistin levels. South Asians had lower BMI, body weight, and waist circumference compared with all other racial/ethnic minority groups except

Full Text available with Trip Pro

2018 American Heart Association

116. Timing of Operative Debridement for Necrotizing Soft Tissue

. Address for reprints: Rondi B. Gelbard, MD, Emory University School of Medicine, 69 Jesse Hill Jr. Drive, SE, Glenn Memorial Building, Room 315, Atlanta, Georgia 30303; email: . Abstract BACKGROUND Necrotizing soft tissue infections (NSTI) are rare, life-threatening, soft-tissue infections characterized by rapidly spreading inflammation and necrosis of the skin, subcutaneous fat, and fascia. While it is widely accepted that delay in surgical debridement contributes to increased mortality (...) Fields] OR “methods”[MeSH Terms])) AND ((“necrosis”[MeSH Terms] OR “necrosis”[All Fields]) AND (“mortality”[Subheading] OR “mortality”[All Fields] OR “mortality”[MeSH Terms])) AND ((“time”[MeSH Terms] OR “time”[All Fields]) AND Factors[All Fields]) OR “necrosis” [MeSH Terms] OR “necrosis”[All Fields] AND (“debridement” [MeSH Terms] OR “debridement”[All Fields]) AND timing[All Fields]. In addition to the electronic search, we hand-searched the bibliographies of recent reviews and articles. FIGURE 1

2018 Eastern Association for the Surgery of Trauma

118. Renal Cell Carcinoma

of TFEB- ampli?ed RCCs that occur in older patients. These tumours pre- sented high-grade eosinophilic cells with necrosis and papillary or pseudopapillary architecture. The expression of melanocytic markers is variable and FISH analyses revealed high levels of TFEB gene ampli?cation. The prognosis of such tumours is poor with usually advanced stage and metastatic outcome [10]. Collecting duct carcinoma (CDC) or Bellini duct carcinoma remains a highly aggressive RCC arising from the renal collecting (...) | Escudier et al.• the presence of necrosis; • the presence of microscopic vascular invasion; • the pathological tumour, node and metastasis (pTNM) staging and • description of the non-neoplastic renal tissue. Biology Beyond the classical one gene–one histology paradigm, a more complex biological classi?cation of RCC (and especially of its clear cell histotype) is emerging [14]. First, RCC proved to be an extremely heterogeneous disease [15]; beyond the seminal genetic alteration (mutation, deletion

2019 European Society for Medical Oncology

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>